Methods and compositions for treatment of zika virus infection
View Patent ↗Disclosed are 9-deazaaadenine derivatives of the general formula (I) and pharmaceutically acceptable salts thereof, wherein A is OH or NH 2 , and B is H or NH 2 . Methods for treating, preventing and/or suppressing a Zika virus infection with the compounds disclosed are also provided. Pharmaceutical compositions comprising the disclosed compounds are also provided. Such pharmaceutical compositions may optionally contain one or more additional active agents.
1. A method of reducing the transmission of a Zika virus infection from a first subject to a second subject, the method comprising the step of administering to the first subject or the second subject an effective amount of a compound of formula I or a pharmaceutically acceptable salt, hydrate or solvate thereof
wherein A is OH or NH 2 , and B is H or NH 2 .
2. The method of claim 1 , wherein A is NH 2 and B is H.
3. The method of claim 1 , wherein the second subject is a sexual partner of the first subject.
4. The method of claim 1 , wherein the first subject is a male and the second subject is a female.
5. The method of claim 4 , wherein the Zika virus infection is transmitted from the first subject to the second subject through transmission of a bodily fluid of the first subject to the second subject.
6. The method of claim 5 , wherein the bodily fluid is blood, semen, seminal fluid, or saliva.
7. The method of claim 4 , wherein the compound of formula I is administered to the second subject.
8. The method of claim 7 , wherein transmission of the Zika virus by the second subject is reduced.
9. The method of claim 1 , wherein the first subject is a female and the second subject is an infant or a prenatal human.
10. The method of claim 9 , wherein the Zika virus infection is transmitted from the first subject to the second subject through transmission of a bodily fluid of the first subject to the second subject.
11. The method of claim 10 , wherein the bodily fluid is blood, blood plasma, blood serum, amniotic fluid, breast milk, vaginal secretions, urine, amniotic fluid, or saliva.
12. The method of claim 9 , wherein the compound of formula I is administered to the first subject.
13. The method of claim 12 , wherein the administration reduces a viral titer of the Zika virus in a bodily fluid of the first subject.
14. The method of claim 13 , wherein the bodily fluid is blood, blood plasma, blood serum, amniotic fluid, breast milk, vaginal secretions, urine, amniotic fluid, or saliva.
15. The method of claim 1 , wherein the compound of formula I is administered to the first subject or the second subject after the first or second subject has been infected with the Zika virus infection or after the first or second subject has been infected with the Zika virus and before the Zika virus infection can be detected.
16. The method of claim 1 , wherein a single dose of the compound of formula I is administered during a course of treatment.
17. The method of claim 1 , wherein more than one dose of the compound of formula I is administered during a course of treatment.
18. The method of claim 17 , wherein the course of treatment comprises administering at least one dose as a loading dose and at least one dose as a maintenance dose.
19. The method of claim 1 , wherein the compound of formula I is administered by intravenous administration, intramuscular administration, parenteral administration, oral administration or a combination of the foregoing.
20. A method for reducing a viral titer of a Zika virus in a bodily fluid, tissue or cell of a subject, the method comprising the step of administering to the subject an effective amount of a compound of the formula 1 or a pharmaceutically acceptable salt, hydrate or solvate thereof
wherein A is OH or NH 2 , and B is H or NH 2 .
21. A method of treating or suppressing a disease or condition associated with a Zika virus infection in a subject, the method comprising the step of administering to the subject an effective amount of a compound of the formula I or a pharmaceutically acceptable salt, hydrate or solvate thereof
wherein A is OH or NH 2 , and B is H or NH 2 .
22. The method of claim 21 , wherein the disease or condition is a neurological complication, an auto-immune disease, Guillain-Barré syndrome, or and microcephaly.